KMT2A and leukemia: IGF2BP3 did not only show increased expression in MLL-positive B-ALLs [49] but a treatment with I-BET151, which has been described as effective treatment for MLL-positive leukemias [62], showed a dose-dependent reduction of IGF2BP3 as well as a stagnation of the leukemic cells in the G1-S phase [63].